The prognosis of gastric mesenchymal tumor is related to the early or late detection of gastric mesenchymal tumor and the risk of recurrence of the tumor itself, and is also influenced by the targeted drug imatinib mesylate. Gastric mesenchymal tumors are the most common tumors of mesenchymal tissue origin in the GI tract and have malignant potential. The risk of tumor is related to tumor site, size, tumor cell nuclear division image and the presence of distant node metastasis. The only curable method for gastric mesenchymal tumor is surgical resection. For patients with high risk of recurrence of mesenchymal tumor, the rate of recurrence and metastasis after surgery is high, up to 55%-90%. 80% of patients have local recurrence within 1-2 years after surgery, and half of them may have liver metastasis at the same time, which can be resected again, but it is difficult to improve the survival rate. If the tumor is small at the time of discovery, with few nuclear splitting images, and the primary focus can be completely surgically removed, the 5-year survival rate is about 50%-65%; the 5-year overall survival of those who cannot completely remove the primary focus and metastases is <35%, and the overall survival of those whose primary focus cannot be removed is 9-12 months. For patients with postoperative mesenchymal tumor recurrence median survival is 54 months for patients with complete surgical resection and 5 months for patients with incomplete resection. Imatinib mesylate is an effective agent for the treatment of patients with drug-sensitive gastrointestinal mesenchymal tumors and is effective in improving survival in patients with postoperative recurrent or metastatic gastric mesenchymal tumors. In conclusion, don't be nervous after the discovery of gastric mesenchymal tumor, timely and effective treatment has a good prognosis, and you should keep a positive and optimistic attitude to face it.